Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 35, Issue 6, 2005, Pages 583-586

  Trenschel, Rudolf ^a   Ditschkowski, M ^a   Elmaagachi, A H ^a   Koldehoff, M ^a   Ottinger, H ^a   Steckel, N ^a   Hlinka, M ^a   Peceny, R ^a   Rath, P M ^a   Dermoumi, H ^a   Beelen, D W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Allogeneic SCT; Caspofungin; Cyclosporin A; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; C REACTIVE PROTEIN; CASPOFUNGIN; CIPROFLOXACIN; CREATININE; CYCLOSPORIN A; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; METRONIDAZOLE; MONOCLONAL ANTIBODY; PREDNISOLONE; VORICONAZOLE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER FAILURE; MALE; MEDICAL DOCUMENTATION; MYCOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SIDE EFFECT; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; C-REACTIVE PROTEIN; CREATINE; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FEVER; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOSES; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 20144389791     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704859     Document Type: Article

References (18)

1. Groll AH, Walsh TJ. Potential new antifungal agents. Curr Opin Infect Dis 1997; 10: 449-454.
2. Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999; 44 151-162.
3. Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology 2001, 351-361.
4. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5: 120-235.
5. Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107-1114.
6. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
7. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001; 55: 633-638.
8. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35: 79-86.
9. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002; 24: 351-359.
10. Arathoon EG, Gotuzzo E, Noriega LM et al. A randomized, double-blind, multicenter study of caspofungin versus amphotericin in the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451-457.
11. Sable CA, Nguyen B-YT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25-31.
12. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-1535.
13. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299.
14. Maertens J, Raad I, Petrikkos G et al. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungals: an analysis of 90 patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, San Diego, CA. Poster M-868, 2002.
15. Cancidas™ [package insert]. Merck & Co., Inc.: Whitehouse Station, NJ, 2001.
16. Mora-Duarte J, Robert Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
17. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692-1696.
18. Sobel JD. Practice guidelines for the treatment of fungal infections. Clin Infect Dis 2000; 30: 652.